NASDAQ:MITO
Delisted
Stealth BioTherapeutics Corp Stock News
$0.320
+0 (+0%)
At Close: Feb 14, 2023
Good Penny Stocks to Buy Today? 3 to Watch Right Now
03:16pm, Wednesday, 08'th Jun 2022
Here are three penny stocks to watch right now The post Good Penny Stocks to Buy Today? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Stealth BioTherapeutics Shares Are Surging Today?
09:47am, Wednesday, 08'th Jun 2022
Stealth BioTherapeutics Corp (NASDAQ: MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a signif
10 Biggest Price Target Changes For Monday
11:52am, Monday, 23'rd May 2022 Benzinga
Telsey Advisory Group reduced DICK'S Sporting Goods, Inc. (NYSE: DKS) price target from $153 to $125. Dick's Sporting shares rose 2.7% to $79.62 in pre-market trading.
Piper Sandler lowered the pric
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
What to Know About Buying Penny Stocks on May 10th
12:00pm, Tuesday, 10'th May 2022 PennyStocks
Here's what you need to know about trading penny stocks today
The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
What to Know About Buying Penny Stocks on May 10th
08:00am, Tuesday, 10'th May 2022
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
09:25am, Monday, 02'nd May 2022
Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degen
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
11:53am, Thursday, 17'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis
AbbVie, Inc. (NYSE: ABBV) announced
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
05:00pm, Wednesday, 09'th Mar 2022
BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
07:30am, Tuesday, 22'nd Feb 2022
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies
Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
06:00pm, Thursday, 10'th Feb 2022 Benzinga
New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
07:30am, Tuesday, 04'th Jan 2022
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies
Orgenesis (NASDAQ:ORGS) versus Stealth BioTherapeutics (NASDAQ:MITO) Head to Head Comparison
02:16am, Thursday, 23'rd Dec 2021 Dakota Financial News
Orgenesis (NASDAQ:ORGS) and Stealth BioTherapeutics (NASDAQ:MITO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Analyst Ratings This is a summary of current ratings for Orgenesis and Stealth BioTherapeutics, as provided []
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
01:25pm, Thursday, 11'th Nov 2021
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
09:14am, Wednesday, 20'th Oct 2021
Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth syndro